Definitive Healthcare (NASDAQ:DH – Get Free Report) had its price target lowered by stock analysts at Deutsche Bank Aktiengesellschaft from $7.00 to $5.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 28.53% from the company’s current price.
Several other equities research analysts have also commented on DH. JPMorgan Chase & Co. lowered shares of Definitive Healthcare from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $7.00 to $5.00 in a research note on Wednesday, July 31st. William Blair reissued an “outperform” rating on shares of Definitive Healthcare in a report on Tuesday, May 14th. Canaccord Genuity Group cut their price target on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, May 8th. Barclays reduced their target price on Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Morgan Stanley decreased their price objective on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.55.
Check Out Our Latest Stock Report on Definitive Healthcare
Definitive Healthcare Stock Up 1.6 %
Definitive Healthcare (NASDAQ:DH – Get Free Report) last released its earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. The firm had revenue of $63.70 million during the quarter, compared to analysts’ expectations of $63.19 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. Definitive Healthcare’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 EPS. Analysts predict that Definitive Healthcare will post 0.09 EPS for the current fiscal year.
Hedge Funds Weigh In On Definitive Healthcare
Several institutional investors and hedge funds have recently made changes to their positions in the business. Conestoga Capital Advisors LLC boosted its stake in Definitive Healthcare by 1.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 5,595,627 shares of the company’s stock valued at $45,157,000 after purchasing an additional 74,490 shares during the period. Vanguard Group Inc. raised its stake in Definitive Healthcare by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 4,535,377 shares of the company’s stock valued at $36,600,000 after acquiring an additional 67,068 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Definitive Healthcare by 28.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company’s stock worth $24,168,000 after acquiring an additional 976,279 shares during the period. Raymond James & Associates grew its stake in shares of Definitive Healthcare by 41.6% in the first quarter. Raymond James & Associates now owns 844,814 shares of the company’s stock worth $6,818,000 after purchasing an additional 248,266 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Definitive Healthcare by 1.9% during the second quarter. Victory Capital Management Inc. now owns 509,009 shares of the company’s stock valued at $2,779,000 after purchasing an additional 9,316 shares during the period. 98.67% of the stock is currently owned by hedge funds and other institutional investors.
About Definitive Healthcare
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Read More
- Five stocks we like better than Definitive Healthcare
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Investing in Travel Stocks Benefits
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.